The increased hepatic expression of genes associated with fatty acid oxidation in peroxisome and mitochondria (SLC27A5, ABCD1, ACOT8, ACSM1, ACSM3 and ACSM5) found in response to the supplementation with CMA suggests that this multi-ingredient treatment would tackle NAFLD by boosting this catabolic pathway in both organelles. Here, ACSM3 is linked to metabolic dysfunction-associated steatotic liver disease.